LRRK2 and Parkinson disease: In this context, fibroblasts from PD patients with the G2019S LRRK2 mutation show elevated mitophagy due to the activation of class III HDACs, while sPD fibroblasts exhibit downregulation of damaged mitochondrial clearance [318].